ArticleInternational journal of qualitative studies on health and well-being2024
'I haven't discussed anything with anyone': lived experience of long-term users of benzodiazepine receptor agonists regarding their treatment for substance use disorder.
Article in International journal of qualitative studies on health and well-being, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Patient experiences of benzodiazepine tapering: a qualitative study of treatment in addiction care.BMC psychiatry · 2026Article
- Barriers to discontinuing benzodiazepine receptor agonists in older adults: a survey of older adults across Europe.Age and ageing · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTreatment for substance use disorder (SUD) to benzodiazepine receptor agonists (BZRA) can be challenging and lengthy. BZRA are prescribed for anxiety and insomnia, and though guidelines recommend an initial prescription duration of one to four weeks, this is frequently longer. Understanding the multiple challenges associated with withdrawing from BZRA and exploring the nuance and complexities from the patient's perspective is crucial.
methodsIn this study, we explore the experiences of SUD to BZRA with nineteen users, who have subsequently either stabilized, reduced, or discontinued their usage. The data were analysed using Interpretative Phenomenological Analysis.
findingsOur study identified five key themes regarding the long-term use of BZRA which address inadequate patient information, strict adherence to prescribed medication, minimal involvement in cessation plans, respecting patient readiness for tapering and personalized tapering approaches.
conclusionThese findings indicate that patients' blind trust in their providers can prevent them from voicing concerns, highlighting the importance of an authentic and collaborative relationship between the patient and healthcare provider, while respecting patient autonomy. The goal-oriented care approach could improve BZRA management by aligning treatment with individual goals, enhancing satisfaction, and addressing the complexities of long-term use and withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.